Two deaths and additional serious adverse events have been attributed to the use of NeutroSpec (technetium 99m-fanolesomab), a monoclonal antibody-labeled radiopharmaceutical agent approved in the U.S. for the diagnosis of equivocal appendicitis.
Two deaths and additional serious adverse events have been attributed to the use of NeutroSpec (technetium 99m-fanolesomab), a monoclonal antibody-labeled radiopharmaceutical agent approved in the U.S. for the diagnosis of equivocal appendicitis.
Palatin Technologies of Cranbury, NJ, and Tyco Mallinckrodt Healthcare, a unit of Tyco International, issued a warning about the deaths Nov. 30. According to the announcement, Mallinckrodt received reports of the two deaths and additional cases of serious cardiopulmonary adverse reactions including cardiac arrest, hypoxia, and hypotension.
The deaths and severe reactions happened within 30 minutes of injection. The onset, according to the announcement, generally occurred within minutes of injection and required resuscitation with fluids, vasopressors, and oxygen. A majority of the incidents involved patients with underlying cardiopulmonary disease and off-label applications, the company said. The company did not disclose the number of non-fatal adverse events.
The firm warned physicians that patients receiving NeutroSpec should be closely monitored for at least one hour after administration. Resuscitation equipment and appropriately-trained personnel should be readily available during that time.
The firm said it is working with the FDA to review cases and revise safety information on its package labeling. The FDA posted a notice about the incidents on its Web site on Dec. 1.
NeutroSpec is indicated for scintigraphic imaging of patients with equivocal symptoms of appendicitis who are at least five years of age. The technetium-labeled anti-CD15 monoclonal antibody selectively binds to neutrophils (a type of white blood cell) involved in immune response.
The FDA approved NeutroSpec for diagnosis of equivocal appendicitis in July 2005. It was the first agent related to noninvasive diagnosis of infection to be approved by the agency in more than two decades.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.